DPCO LIST NOTIFICATIONMrgPharma
LATEST DPCO NOTIFICATION
(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)
New Delhi, the 18th May, 2016
S.O.1816(E) – In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
|Sl. No.||Name of the Scheduled Formulation||Strength||Unit||Ceiling Price (Rs.)|
|1||Hydroxychloroquine Tablet||Hydroxychloroquine -200 mg||1 Tablet||5.50|
|2||Sulfasalazine Tablet||Sulfasalazine -500 mg||1 Tablet||3.70|
|3||Dexamethasone Tablet||Dexamethasone -0.5 mg||1 Tablet||0.18|
|4||Prednisolone Tablet||Prednisolone -5mg||1 Tablet||0.52|
|5||Prednisolone Tablet||Prednisolone -10mg||1 Tablet||0.90|
|6||Phenytoin||Phenytoin -100 mg||1 Tablet||1.27|
|7||Amoxicillin Capsule||Amoxicillin -500mg||1 Capsule||5.70|
Clavulanic Acid Tablet
|9||Amoxicillin+ Clavulanic Acid
Powder for Injection
|10||Cefixime Tablet||Cefixime -200mg||1 Tablet||8.48|
|11||Metronidazole Tablet||Metronidazole -400mg||1 Tablet||0.75|
|14||Folic Acid Tablet||Folic Acid -5mg||1 Tablet||1.28|
|15||LAmiodarone Tablet||Amiodarone -200mg||1 Tablet||10.51|
|16||LSodium Nitroprusside Injection||Sodium Nitroprusside -10mg/ml||1 ml||23.95|
|17||Digoxin Tablet||Digoxin -0.25mg||1 Tablet||1.11|
|18||Omeprazole Capsule||Omeprazole -20mg||1 Capsule||2.31|
|19||Oral Rehydration Salts||(As Licensed)||1 Gram||0.71|
|20||Insulin (Soluble) Injection||Insulin (Soluble)-40IU/ml||1 ml||13.34|
|21||Intermediate Acting (NPH)
|22||Premix Insulin (30:70)
(Regular : NPH) Injection
|Premix Insulin (30:70)
(Regular : NPH) -40IU/ml
|23||Carbimazole Tablet||Carbimazole -10mg||1 Tablet||3.42|
|24||Mifepristone Tablet||Mifepristone -200mg||1 Tablet||298.49|
(a) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(b) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
(c) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V as per paragraph 24 (2) of the DPCO, 2013.
(d) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table, launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(e) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(f) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Price Control) Order, 2013 read with Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
- No. 8(31)/2016/D.P./NPPA-Div.II